Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Shire Will Pay Up to $325M to Buy FerroKin

By Pharmaceutical Processing | March 16, 2012

NEW YORK (AP) — Irish drugmaker Shire plc said Thursday it will pay $100 million to acquire FerroKin BioSciences Inc., a company that is developing a drug that helps the body eliminate excess iron.

Shire said it will pay $100 million upfront for FerroKin, and it could pay as much as $225 million more if the company’s main drug candidate progresses through clinical testing, gets approved, and reaches sales targets. FerroKin is developing a drug that is designed to reduce iron levels for adults and children who have received several blood transfusions. The drug is in mid-stage clinical testing, and Shire said it could be approved as early as 2016. FerroKin was founded in 2007 and is based in San Carlos, Calif.

FerroKin’s drug is an oral capsule that is taken once per day. Shire said the drug has received orphan drug incentives in both the U.S. and the European Union, meaning the regulatory process could be sped up and the product will get years of marketing exclusivity if it is approved.

Shire said it wants to begin marketing the drug for use by patients with myelodysplastic syndrome, a disease that affects the production of blood cells, and hemoglobinopathies, which are genetic conditions that affect hemoglobin, the oxygen-carrying protein in red blood cells.

Shares of Shire fell $1.81 to $101.50 in afternoon trading.

 

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards